Centhaquine Increases Stroke Volume and Cardiac Output in Patients with Hypovolemic Shock

3 Aman Khanna¹, Krish Vaidya², Dharmesh Shah³, Amaresh K. Ranjan^{4*} and Anil Gulati^{4,5,6*}

- 4 ¹ Aman Hospital and Research Centre Organization, Vadodara, Gujarat, INDIA
- ⁵ ² I cure Heart care, Vadodara, Gujarat, INDIA
- ⁶ ³ Pharmazz India Pvt. Ltd., Greater Noida, UP, INDIA.
- ⁴Pharmazz Inc. Research and Development, Willowbrook, IL, USA.
- ⁵Department of Bioengineering, The University of Illinois at Chicago, Chicago, IL, USA.
- 9 ⁶Midwestern University, Downers Grove, IL, USA.

10 ***Correspondence:**

11 anil.gulati@pharmazz.com & amaresh.ranjan@pharmazz.com

12 Keywords: Centhaquine, Cardiac Output, Venous Return, Blood Pressure, Shock,

- 13 Hypovolemia, Resuscitation, Critical Care.
- 14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Abstract

31 Background: Centhaquine is a resuscitative agent that acts on $\alpha 2B$ adrenergic receptors to enhance 32 venous return in hypovolemic shock. The effect of centhaquine on cardiac output in patients with 33 hypovolemic shock has not been reported.

Methods: Trans-thoracic echocardiography was utilized to measure stroke volume (SV), cardiac output (CO), left ventricular outflow tract-velocity time integral (LVOT-VTI), left ventricular outflow tract diameter (LVOTd), heart rate (HR), left ventricular ejection fraction (LVEF), left ventricular fractional shortening (FS) and inferior vena cava (IVC) diameter before (0 min) and after centhaquine (0.01 mg/kg, iv infusion over 60 min) treatment (60 min, 120 min, and 300 min) in 12 randomly selected patients with hypovolemic shock enrolled in a prospective, multicenter, open-label phase IV clinical

- 40 study (NCT05956418) of centhaquine in patients with hypovolemic shock.
- 41 Results: A significant increase in SV (mL) was observed after 60, 120, and 300 minutes of centhaquine

42 treatment. CO (mL/min) increased significantly at 120 and 300 min despite a decrease in HR at these

43 times. A significant increase in IVC diameter and LVOT-VTI (mL) at these time points was observed,

44 which indicated increased venous return. The LVEF and FS did not change, while the mean arterial

45 pressure (MAP, mmHg) increased in patients after 120 and 300 minutes of centhaquine treatment.

46 Positive correlations between IVC diameter and SV ($R^2 = 0.9556$) and between IVC diameter and MAP

47 ($R^2 = 0.8928$) were observed, which indicated the effect of centhaquine mediated increase in venous

48 return on SV, CO, and MAP.

49 Conclusions: Centhaquine mediated increase in venous return appears to play a critical role in 50 enhancing SV, CO, and MAP in patients with hypovolemic shock; these changes could be pivotal for 51 reducing shock-mediated circulatory failure, promoting tissue perfusion, and improving patient 52 outcomes.

53 Trial registration: The phase IV trial reported in this study has Clinical Trials Registry, India; 54 ctri.icmr.org.in, CTRI/2021/01/030263; clinicaltrials.gov, NCT05956418.

- 55
- 56
- 57
- 51
- 58
- . .
- 59
- 60
- 61
- 62
- 63
- 64

65

66 1 Introduction

67 Hypovolemic shock decreases circulating blood volume and reduces stroke volume (SV), cardiac output (CO)[1], and tissue blood perfusion, leading to the possibility of organ failure and death. 68 69 Managing hypovolemic shock is critical and involves prompt and targeted interventions to restore the 70 circulating blood volume and increase organ perfusion using various fluids and vasopressors[1; 2]. 71 Although the commonly used fluids (crystalloids or colloids) help compensate for the volume loss, 72 patients often require vasopressors to achieve perfusion endpoints (e.g., CO and MAP)[3]. 73 Vasopressors induce constriction of the blood vessels and aid the sympathetic system to increase blood 74 pressure and CO, in an attempt to increase tissue perfusion[4]. However, the use of vasopressors (e.g., 75 epinephrine, norepinephrine, dopamine, vasopressin, and angiotensin) remains debatable due to 76 associated risks, including cardiac arrhythmias, decreased tissue perfusion, fluid extravasation, and 77 organ failure [5].

At the normal physiological state, a significant amount of blood is pooled on the venous side (having high vascular capacitance) of the circulation; however, in hypovolemic shock, blood accumulation in the veins is further increased, and that a significant amount of blood does not participate in tissue perfusion[6]. It is of interest to divert the pooled venous blood towards the arterial side so that the circulating blood volume can be increased, which will help increase stroke volume (SV), cardiac output

83 (CO), and mean arterial pressure (MAP), as well as increase tissue perfusion.

84 Centhaquine (2-[2-[4-(3-Methylphenyl)-1-piperazinyl]ethyl] quinoline citrate) is being developed to treat hypovolemic shock. It showed good tolerability and safety in healthy subjects with minimal 85 86 adverse effects observed at almost ten times the therapeutic dose (NCT02408731). Clinical studies in hypovolemic shock patients (NCT04056065 and NCT04045327) found that centhaquine significantly 87 88 increased HR and MAP, reduced lactate levels, and increased survival[7; 8]. The proposed mechanism 89 of action of centhaquine is by acting on venous a 2B-adrenergic receptors; it augments the blood return 90 to the heart and increases SV[9]. In swine and rat models of hypovolemic shock, centhaquine 91 significantly increased the SV, leading to increased CO and MAP [10; 11] and improved survival. The 92 current study investigates centhaquine's role in increasing cardiovascular variables (SV, CO, and MAP) 93 by enhancing venous blood return in human patients with hypovolemic shock.

94 2 Materials and methods

95 2.1 Study Design

96 This pilot study was conducted on 12 randomly selected patients enrolled in a prospective, multicenter, 97 open-label phase IV clinical study (NCT05956418) of centhaquine in patients with hypovolemic 98 shock. At the baseline, demographic data, chest X-ray, electrocardiogram (ECG), and vital signs were recorded along with blood counts and chemistry. Patients received 0.01 mg/kg centhaquine by 99 100 intravenous infusion over 60 min in 100 mL normal saline. Systolic and diastolic blood pressure (SBP 101 and DBP) were recorded using a sphygmomanometer at baseline, hourly for the initial 48 hrs, and in 102 between if needed. The mean arterial pressure [DBP + 1/3 (SBP - DBP)] and pulse pressure (SBP-103 DBP) were calculated.

104 The ongoing phase IV study is an open label study aimed at assessing the post-marketing efficacy of 105 centhaquine. All patients in this study received centhaquine along with standard of care for 106 hypovolemic shock. Data from the baseline value in this study was compared. Historical data on fluid

- 107 resuscitation was also used to understand the superiority of resuscitation with centhaquine. The study 108 duration for an individual patient was seven days or earlier (patient discharge).
- 109 2.1.2 Echocardiographic measurements
- 110 Transthoracic echocardiography was utilized to assess SV, CO, HR, left ventricular ejection fraction
- 111 (LVEF), and left ventricular fractional shortening (LVFS) before (0 min) and after centhaquine
- 112 treatment (60 min, 120 min and 300 min). An expert technician conducted the echocardiography, and
- 113 the detailed methodology is as follows -
- 114 2.1.2.1 LVOT diameter: A parasternal long-axis view was obtained to visualize the left ventricular 115 outflow tract (LVOT) and the aortic valve. The view of the aortic valve opening and closing was 116 ensured. The best view of the aortic valve at mid-systole (when the valves are wide open) was ensured, 117 images were captured, and the distance near the aortic annulus at the base of the leaflets was measured 118 using the tool. This measured distance was the diameter of the LVOT.
- 119 2.1.2.2 LVOT VTI (LVOT velocity time integral): The pulse-wave Doppler gate was aligned parallel
- 120 to the LVOT in the Apical 5 Chamber view to obtain the best VTI tracing. Once the Doppler gate was

121 positioned well, the pulse wave Doppler was activated. The automated LVOT VTI was calculated 122 after tracing the outline of one of the systolic waveforms. The values for the LVOT VTI are denoted

- as the distance in centimeters (cm) and represent the distance that blood travels in one heartbeat.
- 124 2.1.2.3 Heart rate (HR): The specific points on the screen corresponding to individual heartbeats were
 125 marked, and the heart rate was automatically calculated by the echocardiography machine based on
 126 this input.
- 127 2.1.2.4 SV and CO: SV was calculated as the product of the LVOT diameter and the LVOT VTI. CO
 128 was calculated as the product of SV and HR.
- 129 2.1.2.5 LVEF and LVFS: LVEF was calculated via visual estimation by reviewing different 130 echocardiography windows, as was done in an emergency setting. LVFS was calculated using the 131 formula (%LVFS = [(LVDD-LVDS)/LVDD] \times 100, where LVDD is the left ventricle diameter at 132 diastole, and LVDS is the left ventricle diameter at systole, measured through echocardiography.
- 133 2.2 Patient population, consent, and regulatory oversight
- 134 The phase IV study's detailed inclusion/exclusion criteria (NCT05956418) are provided at 135 <u>https://clinicaltrials.gov/study/NCT05956418</u>. Adult hypovolemic shock patients aged \ge 18 years with 136 an SBP \le 90 mmHg upon presentation to the emergency room or ICU, receiving standard shock 137 treatment, and having a blood lactate level >2.0 mmol/L were included in the study.
- 138 Informed consent from all enrolled patients or their legally authorized representative (LAR) was
- 139 obtained verbally and in writing after communicating the study details.
- The study adhered to the Harmonization of Technical Requirements for Registration of
 Pharmaceuticals for Human Use Guideline for Good Clinical Practice (ICH-GCP), the Helsinki
 Declaration, and local regulatory requirements.
- 143 2.3 Safety evaluation

144 Safety was evaluated by the study investigators based on adverse events (AEs), physical examination

results, vital signs (including HR, SBP, DBP, body temperature, and respiratory rate), ECG, and clinical variables. Any AEs that occurred or worsened during or after centhaquine treatment were

systematically recorded and coded by system organ class and preferred term using the latest version of

148 the International Conference on Harmonization Medical Dictionary for Regulatory Activities.

149 2.4 Multivariate Imputation by Chained Equations (MICE)

150 Data not available (6.4%) were assessed as "missing values," and they were imputed using "MICE,"

151 which is a package that implements a method to address missing data by creating multiple imputations

152 (replacement values) for multivariate missing data[12]. In this study, five patients had multiple

153 imputations for missing echocardiography data. A scalar of 20, given the number of iterations and

154 predictive mean matching "pmm," was used.

155 2.5 Statistical analysis

156 The results are presented as the mean \pm standard error of the mean (SEM). The statistical analysis was

157 performed using GraphPad Prism 10.1.2 (GraphPad, San Diego, CA, USA). Parametric analysis was

carried out using a one-way analysis of variance without assuming equal variances with a normal

159 probability distribution. The post hoc Tukey's multiple comparisons test was performed to estimate

the significance of differences. p values < 0.05 were considered to indicate statistical significance at

161 the 95% confidence level.

162 **3 Results**

3.1 Patient demographics, baseline characteristics, and volume of fluid administration during the first 5 hours of resuscitation.

165 The demographics and baseline characteristics are shown in Table 1.

166 3.2 Centhaquine Increases Stroke Volume, Cardiac Output, and Mean Arterial Pressure

167 At baseline (0 min), the mean SV (mL) was 63.36 ± 4.06 . At 60 min, 120 min, and 300 min, the mean 168 SV (mL) was 78.07 ± 4.98 ($\Delta 23.2\%$, p=0.0084), 83.51 ± 3.78 ($\Delta 31.8\%$, p=0.0002), and 89.18 ± 3.71 169 ($\Delta 40.74\%$, p<0.0001), respectively (Fig. 1A).

170 The mean CO (mL/min) at baseline was 5728.58 ± 263.4 . At 60 min, 120 min, and 300 min, the mean

171 SV (mL) was 6273.91 ± 318.33 ($\Delta 9.52\%$, p=0.3097), 7212.74 ± 291.2 ($\Delta 25.9\%$, p=0.0002), and 172 7004.28 ± 255.36 ($\Delta 22.23\%$, p=0.0013), respectively (Fig. 1B).

173 At baseline, the mean HR (bpm) was 92.08 ± 3.55 . At 60 min, 120 min, and 300 min, the mean HR

(bpm) was 81.33 ± 2.23 ($\Delta 11.69\%$, p=0.0006), 82.1 ± 0.96 ($\Delta 10.97\%$, p=0.0015) and 79.42 ± 1.80

175 (Δ 13.41%, p<0.0001), respectively (Fig. 1C).

176 MAP (mmHg) at baseline or 0 min was 58.89 ± 1.03 . At 60 min, 120 min, and 300 min, the MAP

177 values were 62.22 \pm 1.44 (Δ 5.66%, p=.4601), 68.33 \pm 1.86 (Δ 16.04%, p=0.0015), and 69.27 \pm 2.4

178 (Δ 17.64%, p=0.0005), respectively (Fig. 1D).

179 **3.3 Centhaquine Increases the Venous Return (increase in IVC Diameter)**

- 180 The mean IVC diameter (cm) at baseline was 0.92 ± 0.04 . A change in IVC diameter was observed
- 181 after centhaquine treatment at 60, 120, and 300 min; the mean IVC diameter (cm) was 1.07 ± 0.03
- 182 $(\Delta 15.94\%, p=0.0091), 1.14 \pm 0.02 (\Delta 25.00\%, p<0.0001) and 1.14 \pm 0.03 (\Delta 23.19\%, p<0.0001),$
- 183 respectively (Fig. 2A).

The relationships between "IVC diameter and SV" and "IVC diameter and MAP" were evaluated. A 184

direct correlation ($R^2 = 0.9556$; p=0.02245) between IVC diameter and SV (Fig. 2B) and between IVC 185 diameter and MAP was observed ($R^2 = 0.8928$; p=0.05514) (Fig. 2C). 186

187 3.4 Centhaguine Increases LVOT-VTI (Blood Flow towards Aortic Annulus/Valve)

188 LVOT-VTI (cm) indicates the blood flow from the left ventricle of the heart towards the aorta. LVOT-

- 189 VTI was 18.54 ± 1.11 at the baseline, while it was 21.97 ± 1.05 ($\Delta 18.52\%$, p=0.0159) 24.14 ± 0.76 190 $(\Delta 30.2\%, p<0.0001)$, and 24.9 ± 0.8 ($\Delta 34.15\%, p<0.0001$) at 60 min, 120 min, and 300 min,
- respectively (Fig. 3A). A direct correlation ($R^2 = 0.9796$; p=0.01024) between LVOT-VTI and IVC 191
- 192 diameter was observed (Fig. 3B). LVOT diameter and area remain unchanged (Fig. 3C and D) at these
- 193 time points.

194 4 Discussions

195 The current study was conducted on 12 hypovolemic shock patients from a single cohort phase IV 196 (NCT05956418) study; centhaquine increased SV and decreased HR (Fig. 1A and C) with ~40% 197 increase in SV, which is much higher compared to other studies relying on fluid infusion alone (~ 10 -198 25%) [13; 14]. Kumar et al. demonstrated a 15-25% increase in SV in healthy humans after infusion 199 of 3 liters of normal saline at the rate of 1 liter per hour and observed cardiac inotropic effect of fluids 200 with a ~14% increase in LVEF. On the other hand, in our current study, only 746.12 \pm 87.42 ml of 201 fluid was required for 5 hours (~150 ml per hour) of resuscitation (Table 2), and no change in LVEF 202 and LVFS (suppl fig. 1A and B) was seen, indicating no effect on cardiac inotropy. Thus, centhaquine 203 increases SV independent of the volume of fluids during resuscitation and does not affect cardiac 204 inotropy. Hence, risks of fluid extravasation and cardiac arrhythmia are mitigated [15], which are

205 associated with a higher volume of fluids and using vasopressors to treat shock[16; 17].

206 CO and MAP were increased (Fig. 1B, D, and Suppl Table 1) after centhaquine treatment despite reduced HR and unchanged total peripheral resistance (Suppl Fig. 2), indicating an impact of increased 207 208

- SV on arterial circulation and tissue perfusion. IVC diameter was also significantly increased (Fig. 209 2A), reflecting increased venous return and cardiac preload [18; 19; 20] after centhaquine treatment.
- A direct correlation between IVC diameter and SV ($R^2 = 0.9556$) (Fig. 2B), and IVC diameter and
- 210 211 MAP ($R^2 = 0.8928$) (Fig. 2C) was observed, which indicated an effect of increased venous return on
- 212 SV, CO, and MAP.

213 Furthermore, LVOT-VTI was significantly upregulated after centhaquine treatment, which indicated increased blood flow in the left ventricular outflow tract during systole, leading to enhanced SV[21; 214 215 22]. The increased blood flow towards LVOT could be attributed to increased chronotropy, cardiac 216 inotropy, or venous return. After centhaquine treatment, however, patients were observed with 217 decreased cardiac chronotropy and no change in inotropy (Suppl Fig. 1A and B); hence, increased venous return would be the main reason for the increased LVOT-VTI. The observed direct correlation 218 between IVC diameter and LVOT-VTI (($R^2 = 0.9796$; p=0.01024) (Fig. 3B) has further supported the 219 220 role of centhaquine mediated enhanced venous return in improving blood flow towards LVOT and 221 enhancing SV.

222 Increased venous return and flow in LVOT would increase the blood volume in the arterial system,

leading to increased MAP. Besides blood volume, vascular resistance is also vital for regulating blood
 pressure. Nonetheless, centhaquine treatment demonstrated no significant change in total peripheral
 resistance (Suppl Fig. 2), further supporting the role of centhaquine mediated increased venous return

on arterial blood volume, causing an increase in MAP in patients with hypovolemic shock.

All patients treated with centhaquine in the study showed improved HR, respiratory rate, and body temperature. A reduction in serum lactate, base deficit, and an increase in PO2/FiO2 was observed in hypovolemic shock patients treated with centhaquine (Table 3). Improved patient outcomes were observed with decreased MODS (0.17 ± 0.11 at the time of discharge vs 2.5 ± 0.38 at the baseline), and stabilized hematological, biochemical, and serum electrolyte levels (Suppl Table 1). All 12 centhaquine treated patients recovered and were discharged at 3.1 ± 0.074 days. Thus, the efficacy and safety of centhaquine in hypovolemic shock patients is promising.

234 These findings align with studies in animal models of hypovolemic shock[10; 11; 23; 24; 25], 235 leading to increased venous return, CO, MAP, and tissue perfusion and underscore the significance of 236 venous return in managing shock [26], with centhaquine targeting this through α 2B-AR agonism. Thus, 237 the current study and other studies [22; 23; 24] highlight the importance of venous return for treating 238 shock. The venous return is modulated through the venous tone, which is primarily regulated by the 239 sympatho-adrenergic system, and thus, adrenergic signaling appears to be an important target in 240 treating various types of shock[27; 28; 29; 30]. Interestingly, ARs are distributed distinctly in the 241 arterial and venous systems and play a key role in coordinating the arterial and venous circulation. 242 Most arteries and large veins (e.g., vena cava) are mainly regulated by $\alpha 1/\alpha 2$ -ARs, while peripheral 243 veins are regulated by α 2B-ARs[25; 31; 32; 33]. The high abundance of α 2B-ARs in the peripheral 244 veins highlights their involvement in the constriction of these peripheral veins. The peripheral veins 245 have relatively higher capacitance than central veins (58.95% vs 11.05%) and hence are vital players 246 for regulating venous return and cardiac preload, which proportionately affects SV. Therefore, findings 247 of the study demonstrating increased SV with increased IVC diameter indicate that centhaquine would 248 be acting on the α 2B-ARs present in the peripheral veins and inducing venoconstriction, which would 249 mobilize the unstressed blood present in these veins towards the vena cava and leading to increased 250 blood volume in IVC causing increase in its diameter (Fig. 2A).

251 However, further studies are required to elucidate which specific venous systems are affected after 252 centhaquine treatment. Studies have shown that cutaneous and splanchnic veins, which together 253 constitute the major blood reservoir in the body, respond to various factors, e.g., temperature, stress, 254 arterial blood parameters, and blood pressure[27], elucidating the effect of centhaquine on the 255 individual venous system would help explore its potential further for treatment of different types of 256 shock involving circulatory failure in different regions. Moreover, further randomized controlled trials 257 with larger cohorts are necessary to fully understand centhaquine's effects on venous systems and its 258 potential in treating different types of shock associated with circulatory failure.

259 **5** Conclusions

The increased venous return induced by centhaquine plays a pivotal role in elevating SV, CO, and MAP mediated through increased LVOT-VTI and IVC diameter in patients experiencing hypovolemic shock. An increase in SV, CO, and MAP occurs concurrently with a decrease in heart rate without influencing the inotropic function of the heart. This unique combination of outcomes suggests that centhaquine has remarkable potential to mitigate circulatory failure associated with hypovolemic shock, thereby promoting blood flow and tissue perfusion and improving overall patient outcomes.

266 Understanding centhaquine's distinctive mechanism of action raises the possibility of its development

as a novel resuscitative agent not only for hypovolemic shock but also for other shock types (e.g., septic

shock and vasodilatory shock) that share pathophysiological characteristics involving circulatory failure and hypotension. While further research and clinical studies are needed to fully elucidate

209 failure and hypotension. While further research and clinical studies are needed to fully elucidate 270 centhaquine's effectiveness and safety profile across diverse shock conditions, its ability to enhance

- 270 centraquine's effectiveness and safety profile across diverse snock conditions, its ability to enhance 271 venous return and cardiac performance without undesirable effects on heart rate or inotropy could be
- pivotal for the development of a highly effective and safer resuscitative agent for the treatment of
- 273 shock.

274 **6 References**

- 275 [1] E.M. Snyder, Jr., Management of refractory shock. Calif Med 80 (1954) 13-5.
- [2] K.J. Kalkwarf, and B.A. Cotton, Resuscitation for Hypovolemic Shock. Surg Clin North Am 97 (2017)
 1307-1321.
- [3] S.M. Hollenberg, Vasoactive drugs in circulatory shock. American journal of respiratory and
 critical care medicine 183 (2011) 847-55.
- [4] P.P. Manolopoulos, I. Boutsikos, P. Boutsikos, N. Iacovidou, and K. Ekmektzoglou, Current use and
 advances in vasopressors and inotropes support in shock. Journal of Emergency and Critical Care
 Medicine 4 (2020).
- [5] N. Fage, P. Asfar, P. Radermacher, and J. Demiselle, Norepinephrine and Vasopressin in
 Hemorrhagic Shock: A Focus on Renal Hemodynamics. Int J Mol Sci 24 (2023).
- [6] R.S. Alexander, Venomotor tone in hemorrhage and shock. Circ Res 3 (1955) 181-90.
- [7] A. Gulati, R. Choudhuri, A. Gupta, S. Singh, S.K.N. Ali, G.K. Sidhu, P.D. Haque, P. Rahate, A.R. Bothra,
 G.P. Singh, S. Maheshwari, D. Jeswani, S. Haveri, A. Agarwal, and N.R. Agrawal, A Multicentric,
 Randomized, Controlled Phase III Study of Centhaquine (Lyfaquin((R))) as a Resuscitative Agent
 in Hypovolemic Shock Patients. Drugs 81 (2021) 1079-1100.
- [8] A. Gulati, D. Jain, N.R. Agrawal, P. Rahate, R. Choudhuri, S. Das, D.P. Dhibar, M. Prabhu, S. Haveri,
 R. Agarwal, and M.S. Lavhale, Resuscitative Effect of Centhaquine (Lyfaquin((R))) in Hypovolemic
 Shock Patients: A Randomized, Multicentric, Controlled Trial. Adv Ther 38 (2021) 3223-3265.
- [9] A. Chalkias, Shear Stress and Endothelial Mechanotransduction in Trauma Patients with
 Hemorrhagic Shock: Hidden Coagulopathy Pathways and Novel Therapeutic Strategies. Int J Mol
 Sci 24 (2023).
- [10] Z. Kontouli, C. Staikou, N. Iacovidou, I. Mamais, E. Kouskouni, A. Papalois, P. Papapanagiotou, A.
 Gulati, A. Chalkias, and T. Xanthos, Resuscitation with centhaquin and 6% hydroxyethyl starch
 130/0.4 improves survival in a swine model of hemorrhagic shock: a randomized experimental
 study. Eur J Trauma Emerg Surg 45 (2019) 1077-1085.
- [11] A. Gulati, M.S. Lavhale, D.J. Garcia, and S. Havalad, Centhaquin improves resuscitative effect of
 hypertonic saline in hemorrhaged rats. J Surg Res 178 (2012) 415-23.
- [12] M.J. Azur, E.A. Stuart, C. Frangakis, and P.J. Leaf, Multiple imputation by chained equations: what
 is it and how does it work? Int J Methods Psychiatr Res 20 (2011) 40-9.
- [13] A. Kumar, R. Anel, E. Bunnell, S. Zanotti, K. Habet, C. Haery, S. Marshall, M. Cheang, A. Neumann,
 A. Ali, C. Kavinsky, and J.E. Parrillo, Preload-independent mechanisms contribute to increased
 stroke volume following large volume saline infusion in normal volunteers: a prospective
 interventional study. Crit Care 8 (2004) R128-36.
- [14] A. Carsetti, M. Cecconi, and A. Rhodes, Fluid bolus therapy: monitoring and predicting fluid
 responsiveness. Curr Opin Crit Care 21 (2015) 388-94.

- [15] M. Mandal, Ideal resuscitation fluid in hypovolemia: The quest is on and miles to go! Int J Crit
 Illn Inj Sci 6 (2016) 54-5.
- [16] J.A. Russell, Vasopressor therapy in critically ill patients with shock. Intensive Care Med 45(2019) 1503-1517.
- [17] D. De Backer, P. Biston, J. Devriendt, C. Madl, D. Chochrad, C. Aldecoa, A. Brasseur, P. Defrance,
 P. Gottignies, J.L. Vincent, and S.I. Investigators, Comparison of dopamine and norepinephrine in
 the treatment of shock. N Engl J Med 362 (2010) 779-89.
- [18] M. Lyon, M. Blaivas, and L. Brannam, Sonographic measurement of the inferior vena cava as a
 marker of blood loss. Am J Emerg Med 23 (2005) 45-50.
- [19] S. Sefidbakht, R. Assadsangabi, H.R. Abbasi, and A. Nabavizadeh, Sonographic measurement of
 the inferior vena cava as a predictor of shock in trauma patients. Emerg Radiol 14 (2007) 181-5.
- [20] M. Massalha, R. Faranish, S. Romano, and R. Salim, Decreased inferior vena cava diameter as an
 early marker in postpartum hemorrhage. Ultrasound Obstet Gynecol 59 (2022) 234-240.
- [21] J. Wang, D. Zhou, Y. Gao, Z. Wu, X. Wang, and C. Lv, Effect of VTILVOT variation rate on the
 assessment of fluid responsiveness in septic shock patients. Medicine (Baltimore) 99 (2020)
 e22702.
- [22] A. Perez-Manjarrez, E. Garcia-Cruz, R. Gopar-Nieto, G.M. Jimenez-Rodriguez, E. Lazcano-Diaz, G.
 Rojas-Velasco, and D. Manzur-Sandoval, Usefulness of the velocity-time integral of the left
 ventricular outflow tract variability index to predict fluid responsiveness in patients undergoing
 cardiac surgery. Echo Res Pract 10 (2023) 9.
- [23] M.S. Lavhale, S. Havalad, and A. Gulati, Resuscitative effect of centhaquin after hemorrhagic
 shock in rats. J Surg Res 179 (2013) 115-24.
- [24] P. Papapanagiotou, T. Xanthos, A. Gulati, A. Chalkias, A. Papalois, Z. Kontouli, A. Alegakis, and N.
 Iacovidou, Centhaquin improves survival in a swine model of hemorrhagic shock. J Surg Res 200
 (2016) 227-35.
- [25] M. Geevarghese, 3rd, K. Patel, A. Gulati, and A.K. Ranjan, Role of adrenergic receptors in shock.
 Front Physiol 14 (2023) 1094591.
- [26] A. Chalkias, E. Laou, N. Papagiannakis, V. Spyropoulos, E. Kouskouni, K. Theodoraki, and T.
 Xanthos, Assessment of Dynamic Changes in Stressed Volume and Venous Return during
 Hyperdynamic Septic Shock. J Pers Med 12 (2022).
- 340 [27] P.M. Vanhoutte, The Role of the Systemic Veins: An Update. Phlebology 2 (1987) 61-73.
- [28] T. Shen, and K. Baker, Venous return and clinical hemodynamics: how the body works during
 acute hemorrhage. Adv Physiol Educ 39 (2015) 267-71.
- [29] D.J. Funk, E. Jacobsohn, and A. Kumar, Role of the venous return in critical illness and shock: part
 II-shock and mechanical ventilation. Crit Care Med 41 (2013) 573-9.
- [30] R. Spiegel, Stressed vs. unstressed volume and its relevance to critical care practitioners. Clin
 Exp Emerg Med 3 (2016) 52-54.
- [31] J.A. Giovannitti, Jr., S.M. Thoms, and J.J. Crawford, Alpha-2 adrenergic receptor agonists: a review
 of current clinical applications. Anesth Prog 62 (2015) 31-9.
- [32] X.L. Rudner, D.E. Berkowitz, J.V. Booth, B.L. Funk, K.L. Cozart, E.B. D'Amico, H. El-Moalem, S.O.
 Page, C.D. Richardson, B. Winters, L. Marucci, and D.A. Schwinn, Subtype specific regulation of
 human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100 (1999)
 2336-43.
- [33] L. Hering, M. Rahman, S.A. Potthoff, L.C. Rump, and J. Stegbauer, Role of alpha2-Adrenoceptors
 in Hypertension: Focus on Renal Sympathetic Neurotransmitter Release, Inflammation, and
 Sodium Homeostasis. Front Physiol 11 (2020) 566871.

356

357	7 List of a	bbreviations
358	AR	Adrenergic Receptors
359	SV	Stroke Volume
360	СО	Cardiac Output
361	LVEF	Left Ventricular Ejection Fraction
362	FS	Fractional Shortening (Left Ventricular)
363	IVC	Inferior Vena Cava
364	LVOT	Left Ventricular Outflow Tract
365	VTI	Velocity Time Integral
366	LVDD	Left Ventricle Diameter at Diastole
367	LVDS	Left Ventricle Diameter at Systole
368	DBP	Diastolic Blood Pressure
369	HR	Heart Rate
370	MAP	Mean Arterial Pressure
371	SV	Stroke Volume
372	SVR	Systemic Vascular Resistance
373	SBP	Systolic Blood Pressure
374	SOC	Standard of Care
375	MICE	Multivariate Imputation by Chained Equations
376	MODS	Multiple Organ Dysfunction Syndrome
377	ARDS	Acute Respiratory Distress Syndrome

378 8 Declaration

379 Ethics Approval and Consent to Participate: The study was conducted in compliance with the 380 Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Guideline for Good Clinical Practice (ICH-GCP), the Helsinki Declaration, and local regulatory 381 requirements. The study protocol (PMZ-2010/CT-4.1/2019), version 1.0/ dated October 16, 2019, was 382 approved by the Drugs Controller General of India (DCGI), Directorate General of Health Services, 383 384 Ministry of Health & Family Welfare, Government of India (DCGI CT NOC. No.: CT/ND/110/2020). Besides, each institutional ethics committee reviewed and approved the study protocol before initiating 385 386 patient enrolment. The trial was registered at the Clinical Trials Registry, India 387 (CTRI/2021/01/030263), and the United States National Library of Medicine, ClinicalTrials.gov 388 (NCT05956418). Each site's ethics committee was informed of any protocol deviation, amendment, 389 subject exclusion or withdrawal, and serious adverse events (SAE). (Details of the participating site 390 for this study are in Suppl Table 2)

391 Consent: The patients included in this study were in a state of life-threatening shock; therefore, for 392 patients who were not fit to give consent themselves at the time of treatment initiation, informed 393 consent was obtained from their legally authorized representative (LAR). The investigator verbally, 394 as well as in writing, informed the patient or LAR of the details of the study relevant to a decision 395 about whether to participate in the study.

396 No patient identifiable data is present in this article.

397 9 Conflict of Interest

D.S. is an employee of Pharmazz India Pvt. Ltd., INDIA, and A.K.R. is an employee of Pharmazz,
Inc., Willowbrook, IL, USA. A.G. is an employee of Pharmazz, Inc., Willowbrook, IL, USA, and
has issued and pending patents related to this study. All the other authors declare no competing
interests.

402 **10** Author Contributions

403 Conceptualization: A.G., and D.S.; Data curation: A.G., A.K.R. and D.S.; Formal analysis: A.K.R.,
404 A.G. and D.S.; Investigation: A.K., K.V.; Methodology: A.G., D.S. and A.K.; Project administration:
405 A.K. and D.S.; Visualization: A.G. and A.K.R.; Writing–original draft: A.K.R.; Writing–review &
406 additing: A K.B. A.G. and D.S. All authors read and approved the final manuscript.

406 editing: A.K.R., A.G. and D.S. All authors read and approved the final manuscript.

407 **11 Funding**

408 Pharmazz India Pvt Ltd. supported the study.

409 **12** Acknowledgments

- 410 We acknowledge Sunil Gulati, Pharmazz Inc., USA, for imputing missing data using a package
- 411 "Multivariate Imputation by Chained Equations (MICE)," which implements a method to address
- 412 missing data by creating multiple imputations (replacement values) for multivariate missing data.
- 413
- 414

415	13	Data Availability Statement
-----	----	-----------------------------

- 416 The anonymized patient datasets generated and/or analyzed during the study are available from the 417 corresponding author on a reasonable request from a bona fide researcher/research group.
- **Figure legends:**
- 419 Figure 1. Effects of centhaquine on cardiovascular variables (SV, CO, HR, and MAP).
- 420 * P<0.05, ** P<0.01, *** P<0.001, and **** P<0.0001 compared to 0 min. n= 12.
- 421 Figure 2. Effect of centhaquine on venous return (IVC diameter) and its correlation with SV
- 422 and MAP. * P<0.05, ** P<0.01, *** P<0.001, and **** P<0.0001 compared to 0 min (A). n= 12.
- 423 Figure 3. Effect of centhaquine on blood flow (LVOT-VTI) in LVOT to the aorta and its
- **correlation with IVC diameter.** * P<0.05, ** P<0.01, *** P<0.001, and **** P<0.0001 compared 425 to 0 min (A). n= 12.



- 467
- 468



474 Figure 3



480

Table 1. Baseline characteristics of patients

$A = (v_{0})$	27.12 ± 2.68
Age (years)	57.42 ± 5.08
Body weight (kg)	58.83 ± 1.57
Height (cm)	157.67± 1.2
Body mass index (kg/m ²)	23.64 ± 0.22
Sex	
Men	9 (75%)
Women	3 (25%)
Medical history	
Hypertension	0
Diabetes	0
Renal disorders	0
Respiratory disease	1 (8.33%)
Ischemic heart disease	0
Liver fibrosis	0
Hepatitis (Altered SGPT)	6 (50%)
Preeclampsia	0
Reason for hypovolemic shock	
Gastroenteritis (vomiting, abdominal pain and or diarrhea)	8(66.67%)
Enteric fever	4(33.33%)
Dengue fever	2 (16.67%)
Falciparum malaria	1 (8.33%)
Acute appendicitis	1 (8.33%)
Clinical factors	
Systolic blood pressure (mmHg)	73.87 ± 2.9

Diastolic blood pressure (mmHg)	45.33 ± 1.64	
Heart rate (beats/min)	108 ± 4.4	
ECG	Normal	
Random blood glucose (mg/dL)	104.24 ± 4.75	
Shock index	1.51 ±0.12	
MODS	2.5 ± 0.38	
ARDS	0.08 ± 0.083	
Respiratory rate (breaths/min)	23.5 ± 0.23	
Body temperature (°F)	102.3 ± 0.36	
Blood lactate (mmol/L)	2.5 ± 0.06	
Base deficit (mmol/L)	-1.49 ± 0.06	
Hemoglobin (g/dL)	12.16 ± 0.45	
Hematocrit (%)	37.24 ± 1.26	
Creatinine (mg/dL)	1.13 ± 0.15	
Glomerular filtration rate (mL/min/1.73 m ²)	83.43 ± 7.84	
рН	7.21 ± 0.01	
<i>p</i> CO ₂ (mmHg)	33.17 ± 0.90	
PO2/FiO2	376.75 ± 6.32	

Table 1. Baseline characteristics of patients

481 The data are presented as the mean \pm SEM.

Table 2. Volume of fluids administered to patients before randomization and during the first 5 hours of resuscitation.

Normal saline (mL)	Normal saline with dextrose (mL)	Total volume (mL)
345.7 ± 67.2	400.42 ± 32.42	746.12 ± 87.42
The data are presen	ted as the mean \pm SEM.	

	Baseline	After administration of centhaquine		
Vitals	Day 1	Day 2	Day 3	Day 4
SBP (mmHg)	73.83 ± 2.88	102.17 ± 1.17	110.00 ± 1.74	120.00 ± 1.67
DBP (mmHg)	45.33 ± 1.64	63.17 ± 2.47	69.17 ± 1.49	77.78 ± 1.47
Heart rate (beats/min)	108 ± 4.38	95.5 ± 3.27	92.42 ± 2.30	85.56 ± 1.45
Respiratory rate (breaths/min)	23.5 ± 0.23	21.83 ± 0.65	21.25 ± 0.64	20.11 ± 0.59
Body temperature (°F)	102.28 ± 0.36	99.51 ± 0.64	98.21 ± 0.30	97.57 ± 0.20
Lactate (mM/L)	2.5 ± 0.06	2.02 ± 0.03	1.67 ± 0.04	1.17 ± 0.05
Base deficit (mM/L)	-149 ± 0.06	-0.52 ± 0.09	0.38 ± 0.18	0.43 ± 0.04
PO2/FiO2	376.75 ± 6.32	405.5 ± 1.74	419.45 ± 1.98	427.51 ± 3.05

506 Table 3. Patient vital signs were recorded from day 1 (baseline) through days 3/4.

507 The data are presented as the mean \pm SEM. *DBP* diastolic blood pressure, *SBP* systolic blood 508 pressure.

509

510